Articles
An overview of treatments for pattern baldness and alopecia which will be in the clinical trial stage during 2023. Androgenetic Alopecia Trials Chong Kun Dang Pharmaceutical – We begin the list with a newcomer, previously unannounced. CKD-843 is a new injectable drug being trialed in “alopecia” by the Chong Kun Dang (CKD) Pharmaceutical company of Seoul,…
Read More
A new type of open-source corporation has emerged with an intriguing goal in mind: to leverage the scientific community and hair loss experiencers worldwide to fund and create new treatments for hair loss. New HairDAO Study With Dr. Ralf Paus A recent press release from HairDAO announced their first funded project, which turned out to…
Read More
A new interesting startup aimed at hair growth has emerged, once again, from Korea – KeraMedix. New Study Published By Nature Portfolio On November 19, 2022, the Communications Biology journal of Nature Portfolio published the study “Keratin-mediated hair growth and its underlying biological mechanism” by researchers from Kyung Hee and Konkuk Universities in South Korea. Unbeknownst to…
Read More
Korean company JW Pharmaceutical announces that it will participate in the upcoming Wnt 2022 Conference to unveil hair growth related data. JW0061 Pipeline Drug For Hair Loss Since 2017, it’s been known that the Wnt pathway specialists at JW Pharmaceutical had their sights set on hair regeneration. It was announced in the media that the company…
Read More
A new Korean biotech company seeks to leverage the multi-faceted therapeutic benefit of FK506 to create a newer and safer hair growth drug. As we are gratified to see completely new approaches emerge in the hair growth space, we should also value the strategy of creating new and improved iterations of older hair growth drugs…
Read More
Epibiotech continues to announce important milestones and progress leading up to a Phase 1 clinical trial for its cell therapy in AGA. Innovative Drug Discovery For Hair-Loss Therapy Symposium Earlier this year in June, Epibiotech co-hosted a hair loss research conference in South Korea with Yonsei University’s Pharmaceutical Research Institute. The meeting, titled “Innovative Drug…
Read More
The long awaited phase II results from Kintor’s KX-826 (pyrilutamide) study in males with androgenetic alopecia have surfaced online. KX-826 Phase 2 Results Presentation Several months ago in May, the 28th Annual Meeting of the Chinese Society of Dermatology was postponed from June to the beginning of September 2022. This was the acclaimed conference where…
Read More
A new reality tv series about people seeking solutions for hair loss, alopecia, and other dermatology-related conditions is coming soon to the TLC channel. Reality TV Hair Loss Show Much in the spirit of the “Dr. Pimple Popper” show, the TLC television network is rolling out a new medically-focused reality show featuring three female hair…
Read More
A new drug aimed at the treatment of androgenetic alopecia is entering a phase 1 clinical trial imminently as of August 2022. CU-40101 Phase 1 Clinical Trial Cutia Therapeutics is the latest biotechnology company to emerge from behind the scenes and enter the global race for new androgenetic alopecia therapies. Its candidate molecule CU-40101 is…
Read More
An FDA approved drug is currently being researched for its repurposed potentials in wound regeneration and hair regrowth. 4-Aminopyridine is a prescription medicine used for the treatment of multiple sclerosis. It’s marketed under the brand name Ampyra and is classified as a potassium channel blocker. This compound, also known as 4-AP or dalfampridine, was the…
Read More